SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061271
Filing Date
2023-11-08
Accepted
2023-11-08 17:18:40
Documents
15
Period of Report
2023-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tpst-20231108.htm   iXBRL 8-K 52806
2 EX-99.1 tpst-ex99_1.htm EX-99.1 242345
3 GRAPHIC img73128808_0.jpg GRAPHIC 31265
  Complete submission text file 0000950170-23-061271.txt   501042

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tpst-20231108_pre.xml EX-101.PRE 12672
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tpst-20231108_def.xml EX-101.DEF 13380
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tpst-20231108_lab.xml EX-101.LAB 17070
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tpst-20231108.xsd EX-101.SCH 3176
9 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20231108_htm.xml XML 6246
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 231389280
SIC: 2834 Pharmaceutical Preparations